publication date: Sep. 11, 2020
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.
NCI’s cancer screening trials may be falling victim to the COVID-19 pandemic.
Last week, the institute asked the National Cancer Advisory Board to form an ad hoc group that would provide guidance on screening trials, starting with the Tomosynthesis Mammographic Imaging Screening Trial, TMIST for short (The Cancer Letter, Sept. 4, 2020).
NCI’s publicly announced move to create an ad hoc working group that would review the feasibility and viability of the TMIST trial threatens to undercut this trial, said Mitchell Schnall, co-chair of ECOG-ACRIN Cancer Research Group, the group conducting the study.
Breast cancer screening is beset with controversy, despite strong evidence from multiple randomized trials that screening mammography, in conjunction with modern therapies, reduces breast cancer mortality and treatment morbidity.
I was disappointed to see that you reported on the results of the IMpassion 131 trial, without context. [The Cancer Letter, Sept. 4, 2020]
Honorable Sen. Harris and colleagues,
I write this letter to you as an advocate for women with malignant uterine soft tissue tumors—and to commend you on the introduction of The Uterine Fibroids Research and Education Act in the United States Congress.
- Mays Cancer Center receives renewal of NCI designation
- Justin Leung receives $1.9 million in funds to research DNA damage response
- Surupa Sen Gupta joins Maryland Oncology Hematology
- JNCCN study sheds light on multi-organ adverse events from immunotherapy
- City of Hope scientists combine oncolytic virus and CAR T in solid tumors
- Phase II study of Tabrecta shows positive ORR for NSCLC
- Pralsetinib receives FDA approval for lung cancer with RET gene fusions
- Oncomine Dx Target Test receives FDA approval as first NGS-based companion diagnostic for RET fusion + NSCLC
- FDA issues alert about efficacy and potential safety concerns with atezolizumab in combination with paclitaxel for treatment of breast cancer
- Oncocyte receives final pricing decision for DetermaRx Molecular Test for lung cancer from CMS
- MD Anderson, Xencor collaborate on investigational XmAb drug candidates